Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21616881 | 0.98 | TDP1 (0.58) | CYP1A2CYP2C19CYP2D6TDP1L3MBTL1 | |
| SCHEMBL20854901 | 0.98 | TDP1 (0.58) | CYP1A2CYP2C19CYP2D6TDP1L3MBTL1 | |
| SCHEMBL1856372 | 0.95 | CYP1A2 (0.65) | CYP1A2CYP2C19CYP2D6MEN1CHRM2 | |
| Hydrazine SCHEMBL28285473 | 0.94 | TDP1 (0.54) | CYP1A2CYP2C19CYP2D6TDP1L3MBTL1 | |
| SCHEMBL1307183 | 0.87 | NPC1 (0.62) | CYP1A2CYP2C19CYP2D6MEN1KMT2A | |
| SCHEMBL6790333 | 0.84 | TDP1 (0.71) | CYP1A2CYP2C19CYP2D6TDP1L3MBTL1 | |
| SCHEMBL8862728 | 0.82 | TDP1 (0.75) | CYP1A2CYP2C19TDP1L3MBTL1MEN1 | |
| SCHEMBL8862878 | 0.82 | TDP1 (0.75) | CYP1A2CYP2C19TDP1L3MBTL1MEN1 | |
| SCHEMBL6777483 | 0.82 | TDP1 (0.75) | CYP1A2CYP2C19TDP1L3MBTL1MEN1 | |
| SCHEMBL2604742 | 0.82 | TDP1 (0.75) | CYP1A2CYP2C19TDP1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | UNIV TEXAS (US) | 2020-04-16 | — | — | US | disclosed |
| EP-2796140-B1 | Stabilized Sulforaphane | PHARMAGRA LABS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2796140-A2 | Stabilized Sulforaphane | Pharmagra Labs, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| EP-2532352-A1 | Stabilized Sulforaphane | Pharmagra Labs, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-1869042-B1 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA SA (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| WO-2008008954-A2 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008954-A2 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIOS CONTAINING SAME | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CYP1A2 2413/4885CYP2C19 1714/4885CYP2D6 2165/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | CYP1A2 1529/4885CYP2C19 1779/4885CYP2D6 1357/4885 |
| US-20080312164-A1 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | GGCT, GSTK1, GCLC | CYP1A2 3345/4885CYP2C19 4022/4885CYP2D6 4030/4885 |
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | CYP1A2 1967/4885CYP2C19 3048/4885CYP2D6 2089/4885 |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | HSP90B1, HSP90AB2P, HSP90AB1 | CYP1A2 896/4885CYP2C19 1439/4885CYP2D6 1603/4885 |
| US-20130116203-A1 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME | GGCT, GSTK1, GSTA1 | CYP1A2 2946/4885CYP2C19 3745/4885CYP2D6 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.